Natarajan Sethuraman Sells 1,409 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 1,409 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $20.01, for a total value of $28,194.09. Following the completion of the sale, the insider now directly owns 163,588 shares of the company’s stock, valued at $3,273,395.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Natarajan Sethuraman also recently made the following trade(s):

• On Wednesday, November 13th, Natarajan Sethuraman sold 2,700 shares of Entrada Therapeutics stock. The stock was sold at an average price of $20.04, for a total value of $54,108.00.
• On Wednesday, October 16th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The stock was sold at an average price of $18.00, for a total value of $10,800.00.
• On Monday, September 9th, Natarajan Sethuraman sold 2,642 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.09, for a total value of $39,867.78.
• On Friday, September 6th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.24, for a total value of $9,144.00.

Entrada Therapeutics Price Performance

Shares of Entrada Therapeutics stock opened at $19.96 on Thursday. The business has a 50-day moving average of $16.62 and a 200 day moving average of $15.85. Entrada Therapeutics, Inc. has a 12 month low of $10.75 and a 12 month high of $20.49. The stock has a market capitalization of $746.90 million, a price-to-earnings ratio of 12.55 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The company had revenue of $94.69 million during the quarter, compared to analysts’ expectations of $55.00 million. Equities research analysts anticipate that Entrada Therapeutics, Inc. will post 1.07 earnings per share for the current year.

Analyst Ratings Changes

TRDA has been the subject of a number of research analyst reports. Oppenheimer increased their price target on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, November 6th. HC Wainwright increased their price target on Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th.

Hedge Funds Weigh In On Entrada Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Entrada Therapeutics by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after acquiring an additional 13,742 shares during the period. American Century Companies Inc. boosted its holdings in Entrada Therapeutics by 5.1% during the 2nd quarter. American Century Companies Inc. now owns 384,973 shares of the company’s stock valued at $5,486,000 after acquiring an additional 18,625 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Entrada Therapeutics by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 185,984 shares of the company’s stock valued at $2,972,000 after buying an additional 23,643 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Entrada Therapeutics by 132.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 138,605 shares of the company’s stock valued at $2,215,000 after buying an additional 78,953 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Entrada Therapeutics by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock valued at $1,787,000 after buying an additional 14,838 shares during the period. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.